ADXS Ayala Pharmaceuticals
- 0.555000
- +0.024500+4.62%
Ayala Pharmaceuticals News
Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced s
Ayala Completes Patient Enrollment for Pivotal Desmoid Tumor Study
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, has announced the completion of patient enrollment for its Phase 3 RINGSIDE study, which is evaluating the efficacy of the drug AL102 in treating desmoid tumors.
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment h
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating.
Advaxis Announces Definitive Agreement With Ayala Pharmaceuticals
Express News | Immunome Shares Are Trading Higher After the Company Announced That It Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and AL101 Drug Candidates
Immunome Shares Rise 16% After Acquisition of Potential Tumor Treatment From Ayala Pharmaceuticals
By Chris Wack Immunome shares were up 16% to $19.56 after the company agreed to buy AL102 and related drug candidate AL101 from Ayala Pharmaceuticals. Ayala shares more than doubled to $1.31 in rece
Immunome to Buy AL102, a Phase 3 Asset for Treatment of Desmoid Tumors
Immunome Will Pay Ayala $20M in Cash and $30M in Immunome Common Stk at the Closing and Will Pay Up to an Additional $37.5M in Development and Comml Milestone Payments >IMNM
Immunome Will Pay Ayala $20M in Cash and $30M in Immunome Common Stk at the Closing and Will Pay Up to an Additional $37.5M in Development and Comml Milestone Payments >IMNM
Immunome Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and Related Drug Candidate AL101 From Ayala >IMNM
Immunome Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and Related Drug Candidate AL101 From Ayala >IMNM
Advaxis Cut to Neutral From Buy by Ladenburg Thalmann
Advaxis Cut to Neutral From Buy by Ladenburg Thalmann
Ladenburg Thalmann Downgrades Ayala Pharmaceuticals to Neutral
Ladenburg Thalmann analyst Ahu Demir downgrades Ayala Pharmaceuticals (OTC:ADXS) from Buy to Neutral.
Ayala Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/16/2023 — Ladenburg Thalmann Downgrades Buy → Neutral 05/30/2023 450.74% Ladenburg Thalmann → $4 Upgra
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Dr
Ayala Pharmaceuticals Presents Updated AL102 Results From Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity
Ayala Pharmaceuticals Announces Closing Of Merger With Biosight >ADXS
Ayala Pharmaceuticals Announces Closing Of Merger With Biosight >ADXS
Advaxis GAAP EPS of -$1.82 Beats by $0.37
Press Release: Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enr
Desmoid Tumors Market Report, 2023: Key Players in the Field - Ayala Pharmaceuticals, SpringWorks Therapeutics, Recursion Pharmaceuticals, and More
DUBLIN, Aug. 1, 2023 /PRNewswire/ -- The "Desmoid Tumors - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights into the
Analysis
Price Target
No Data
